Bitte aktiviere Javascript und schalte etwaige Werbeblocker ab

Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Why Pfizer Is Among the Best High-Yield Dividend Stocks on the Market Now: https://g.foolcdn.com/editorial/images/730554/scientists-monitor-showing-virus.jpg

Why Pfizer Is Among the Best High-Yield Dividend Stocks on the Market Now

Some income investors might view Pfizer (NYSE: PFE) stock as a falling knife to be avoided. After all, the big drugmaker's share price has already plunged more than 20% so far this year. Pfizer just

0

Why Pfizer Is Among the Best High-Yield Dividend Stocks on the Market Now: https://g.foolcdn.com/editorial/images/730554/scientists-monitor-showing-virus.jpg

Why Pfizer Is Among the Best High-Yield Dividend Stocks on the Market Now

Some income investors might view Pfizer (NYSE: PFE) stock as a falling knife to be avoided. After all, the big drugmaker's share price has already plunged more than 20% so far this year. Pfizer just

0

7 Reasons to Buy Vertex Pharmaceuticals Stock Now: https://g.foolcdn.com/editorial/images/730532/scientists-in-a-lab.jpg

7 Reasons to Buy Vertex Pharmaceuticals Stock Now

Another quarter, another solid performance from Vertex Pharmaceuticals (NASDAQ: VRTX). The big drugmaker beat consensus estimates for its Q1 results announced on Monday. Vertex's shares subsequently

0

7 Reasons to Buy Vertex Pharmaceuticals Stock Now: https://g.foolcdn.com/editorial/images/730532/scientists-in-a-lab.jpg

7 Reasons to Buy Vertex Pharmaceuticals Stock Now

Another quarter, another solid performance from Vertex Pharmaceuticals (NASDAQ: VRTX). The big drugmaker beat consensus estimates for its Q1 results announced on Monday. Vertex's shares subsequently

0

7 Reasons to Buy Vertex Pharmaceuticals Stock Now: https://g.foolcdn.com/editorial/images/730532/scientists-in-a-lab.jpg

7 Reasons to Buy Vertex Pharmaceuticals Stock Now

Another quarter, another solid performance from Vertex Pharmaceuticals (NASDAQ: VRTX). The big drugmaker beat consensus estimates for its Q1 results announced on Monday. Vertex's shares subsequently

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE

EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE

0

EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023

EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023

0

EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023

EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG

EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23

EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23

0

EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG

EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23

EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23

0

EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png

EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase

EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase

0

EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png

EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share

EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share

0

EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png

EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares

EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares

0

EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png

EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares

EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0